NONOF - Novo Nordisk: Not The Best Investment Right Now But A Great Case Study
2024-05-28 06:19:07 ET
Summary
- Novo Nordisk reported great first quarter results again but free cash flow declined - in part due to high capital expenditures.
- At this point, we can expect the obesity market to continue growing with a high pace, but we should not ignore the increasing competition - not just from Eli Lilly.
- Additionally, the extremely high valuation multiples make Novo Nordisk not a perfect investment at this point.
Novo Nordisk (NVO) is one of the companies and stocks I cover frequently and although my last article was only published three months ago in February 2024 I will provide another update. Novo Nordisk is one of the most interesting stocks and a great case study as it seems very difficult to reach a conclusion whether to invest in the stock or not as the company....
Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study